KDR and glioblastoma: Despite this, data from clinical trials suggest that, in some patients with recurrent GBM treated with bevacizumab or tyrosine kinase inhibitors (e.g., sunitinib [7] which targets VEGFR, c-kit, and PDGFR), improved 6-month progression-free survival rate (PFS) and radio-graphic responses [8–11] can be observed.